LCL161

For research use only.

Catalog No.S7009

21 publications

LCL161 Chemical Structure

CAS No. 1005342-46-0

LCL-161, a small molecule second mitochondrial activator of caspase (SMAC) mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP).

Size Price Stock Quantity  
EUR 144 In stock
EUR 468 In stock
EUR 979 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's LCL161 has been cited by 21 publications

Purity & Quality Control

Choose Selective IAP Inhibitors

Biological Activity

Description LCL-161, a small molecule second mitochondrial activator of caspase (SMAC) mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP).
Targets
cIAP [1] XIAP [1]
In vitro

LCL161 binds to inhibitors of apoptosis proteins (IAPs) with high affinity and initiates the destruction of cIAP1 and cIAP2, which further induces apoptosis via caspase activation. LCL161 modestly inhibits the growth of FLT3-ITD-expressing cells when administered alone, with an IC50 ranging from ~0.5 μM (Ba/F3-FLT3-ITD cells) to ~4 μM (MOLM13-luc+ cells). The potency of LCL161 against the D835Y mutant is observed to be considerably higher, with an IC50 of ~50 nM when tested against Ba/F3-D835Y cells. Treatment of MOLM13-luc+ cells with a combination of LCL161 and PKC412 leads to significantly more killing of cells than either agent alone, with Calcusyn combination indices suggestive of synergy. PKC412 and LCL161 induces apoptosis of MOLM13-luc+ cells. The combination of PKC412 and LCL161 leads to a higher induction of apoptosis than either agent alone. LCL161 is able to override stromal-mediated rescue of mutant FLT3-expressing cells through positive combination with PKC412. LCL161 inhibits the growth of Ba/F3.p210 cells with an IC50 of ~100 nM. The combination of LCL161 and the ABL inhibitor, imatinib, is observed to be synergistic against BCR-ABL-expressing cells. LCL161 also has demonstrated activity against drug-resistant cells expressing point mutations in the target proteins. LCL161 at 1000 nM is able to mostly or completely kill Ba/F3-derived cell lines conferring resistance to PKC412, which express FLT3-ITD harboring point mutations in the ATP-binding pocket of FLT3. LCL161 also shows activity at concentrations ranging from 100 to 1000 nM against Ba/F3 cells expressing various imatinib- and nilotinib-resistant BCR-ABL point mutations. [1] LCL161 is evaluated against the 23 cell lines in the Pediatric Preclinical Testing Program (PPTP) in vitro panel using 96 hr. LCL161 achieves 50% growth inhibition against only 3 of the 23 tested PPTP cell lines under concentration of 10 μM. The three cell lines includes two T-cell ALL cell lines (COG-LL-317 and CCRF-CEM) and an anaplastic large cell lymphoma cell line (Karpas-299), with CCRF-CEM and Karpas-299 showing the lowest relative IC50 values (0.25 and 1.6 μM, respectively). [2] LCL161shows immunomodulatory properties on human immune subsets. T lymphocytes treated with LCL161 demonstrates significantly enhanced cytokine secretion upon activation, with little effect on CD4 and CD8 T-cell survival or proliferation. LCL161 treatment of peripheral blood mononuclear cells significantly enhances priming of naïve T cells with synthetic peptides in vitro. Myeloid dendritic cells undergoes phenotypic maturation upon LCL161 and demonstrates a reduced capacity to cross-present a tumor antigen-based vaccine. These effects are potentially mediated through an observed activation of the canonical and non-canonical NF-κB pathways, following LCL161 with a resulting upregulation of anti-apoptotic molecules. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LOX MknrSpVv[3Srb36gZZN{[Xl? Mmi2NVAxKG2pL3vn NYrld2o2QCCqcoO= M2PVdXBwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJINKSVBzIHTl[5Ji\GG2aX;uJIlvKGi3bXHuJGxQYCClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDtc5V{\SCjdDCxNFAhdWdxa3esJJBwKGGodHXyJFghcHK|IHL5JHdme3Sncn6gZoxwfHSrbnegZY5idHm|aYO= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6M{e4Nkc,OjRyOEO3PFI9N2F-
LOX MXzGeY5kfGmxbjDhd5NigQ>? MmnLPEBpenN? NXmyPVRvWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[2G|cHHz[UA{NzdiYXP0bZZifGmxbjDpckBpfW2jbjDMU3gh[2WubIOgfIVvd2e{YX\0[YQhcW5ibX;1d4Uh[W[2ZYKgPEBpenNiYomg[ox2d3Knc3PlcoNmKGG|c3H5 MkXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEO3PFIoRjJ2MEizO|gzRC:jPh?=
MDA-MB-231 MnOySpVv[3Srb36gZZN{[Xl? NX3Fe4p5Oi53IITvJFExKHWP MVOxPUBpenN? MXjCbY5lcW6pIHHm[olvcXS7IITvJINKSVBzIFLJVlMh\G:vYXnuJIlvKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iVF7GZYxxcGFibHX2[Ywh[XRiMj61JJRwKDFyIIXNJIFnfGW{IEG5JIhzeyCkeTDFUGlUSQ>? M1jFfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEizO|gzLz5{NEC4N|c5OjxxYU6=
BxPC3 M1nm[mZ2dmO2aX;uJIF{e2G7 MknqN{4{KHWP NFm3dFM2KGSjeYO= NGHuS2NRd3SnboTpZZRqd25ib3[gZ49v[XS3bYXtZYIucW6mdXPl[EBkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDgFCFMzDj[YxteyCjdDCzMlMhfU1iYX\0[ZIhPSCmYYnzJIJ6KE2WUzDhd5NigQ>? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6M{e4Nkc,OjRyOEO3PFI9N2F-
HCT15 M{fzdGZ2dmO2aX;uJIF{e2G7 NEnhcJk{NjNidV2= NV;r[GZWPSCmYYnz M4XDTnBwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDF3IHPlcIx{KGG2IEOuN{B2VSCjZoTldkA2KGSjeYOgZpkhVVSVIHHzd4F6 NF3JU4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
SW620 NVnIdHc4TnWwY4Tpc44h[XO|YYm= M3LNcFEvOSC3TR?= MVW1JIRigXN? M2DocnBwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNYPjJyIHPlcIx{KGG2IEGuNUB2VSCjZoTldkA2KGSjeYOgZpkhVVSVIHHzd4F6 NUXFXHlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFM4QDJpPkK0NFg{Pzh{PD;hQi=>
SW620 NYPnWVJ[TnWwY4Tpc44h[XO|YYm= M4DuXlMvOyC3TR?= MljiOUBl[Xm| MWfQc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTW|YzOCClZXzsd{BifCB|LkOgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> NHu3PWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
LOX MYnGeY5kfGmxbjDhd5NigQ>? NX\BNJhsOy5|IIXN NXz3WopROyCmYYnz Mkj6VI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG9ZKGOnbHzzJIF1KDNwMzD1UUBi\nSncjCzJIRigXNiYomgUXRUKGG|c3H5 NEfQfIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
LS180 M3LiWmZ2dmO2aX;uJIF{e2G7 M1O1TFMvOyC3TR?= NXLMTpJrPSCmYYnz MWDQc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMV|E5OCClZXzsd{BifCB|LkOgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> M2rJelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEizO|gzLz5{NEC4N|c5OjxxYU6=
H460 M3SwSWZ2dmO2aX;uJIF{e2G7 MUezMlMhfU1? M2TUdVUh\GG7cx?= MVLQc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzJIF1KDNwMzD1UUBi\nSncjC1JIRigXNiYomgUXRUKGG|c3H5 M{PsZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEizO|gzLz5{NEC4N|c5OjxxYU6=
LOX MVzGeY5kfGmxbjDhd5NigQ>? Ml36NVAxKG2pL3vn MUW4JIhzew>? MnvXVIxie22jIHPvcoNmdnS{YYTpc44hcW5iboXk[UBud3W|ZTD4[Y5w\3KjZoTl[EB4cXSqIHj1cYFvKEyRWDDj[YxteyCjdDCxNFAhdWdxa3esJJBwKG2nYYP1doVlKGG2IEigbJJ{NCCFcDC9JFMvOyEQvF2u MoTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
SW620 NYXu[WdDTnWwY4Tpc44h[XO|YYm= M2\BdFUh\GG7cx?= M3zv[mlv\HWldHnvckBw\iC|ZX7zbZRqgmG2aX;uJI9nKGi3bXHuJHNYPjJyIHPlcIx{KHSxIHPvcoF1fW23bXHiMYlv\HWlZXSgZZBweHSxc3nzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEWg[IF6eyCkeTDNWHMh[XO|YYmsJGVEQTBiPTC2MlY3KM7:TT6= Mm\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
LOX MY\GeY5kfGmxbjDhd5NigQ>? MU[xNFAhdWdxa3e= M{TZVFghcHK| MUfEdpVoKHWydHHr[UBqdiC2dX3vdkBw\iCwdXTlJI1wfXOnIIjlco9oemGodHXkJJdqfGhiaIXtZY4hVE:[IHPlcIx{KGG2IEGwNEBu\y:tZzygdI8hdWWjc4Xy[YQh[XRiODDodpMtKES{dXegeZB1[WunIE2gNVgvPCEQvF2u M2DXZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzPVQxLz5{NEC5N|k1ODxxYU6=
SW620 MorsSpVv[3Srb36gZZN{[Xl? NYDNeYlIOi53IIXN M3XUZlUh\GG7cx?= NELzWWRKdmS3Y4Tpc44hd2Zic3Xud4l1cXqjdHnvckBw\iCqdX3hckBUXzZ{MDDj[YxteyC2bzDjc45ifHWvdX3hZk1qdmS3Y3XkJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBifCB{LkWgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
LOX M4nQe2Z2dmO2aX;uJIF{e2G7 MnHRNVAxKG2pL3vn MnjPPEBpenN? NH35[|JKdiC4aY\vJIlvcGmkaYTpc44hd2ZiWFnBVEBDUVJ{IHTvcYFqdiCrbjDoeY1idiCOT2igZ4VtdHNieHXuc4dz[W[2ZXSgbY4hdnWmZTDtc5V{\SCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjZZNx[XOnIEOvO{Bi[3Srdnn0fUBifCBzMECgcYcwc2duIIDvJIFnfGW{IEigbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> NVTid5ViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM6PDBpPkK0NFk{QTRyPD;hQi=>
LOX MUPGeY5kfGmxbjDhd5NigQ>? NUPzWJhuOTByIH3nM4to M{ezPFghcHK| NFLpfYRKdiC4aY\vJIlvcGmkaYTpc44hd2ZiWFnBVEBDUVJ{IHTvcYFqdiCrbjDoeY1idiCOT2igZ4VtdHNieHXuc4dz[W[2ZXSgbY4hdnWmZTDtc5V{\SCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBk[XOyYYPlJFMwPyCjY4Tpeol1gSCjdDCxNFAhdWdxa3esJJBwKGGodHXyJFghcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
MDA-MB-231 M3XtRWZ2dmO2aX;uJIF{e2G7 MY[wMlM4KHSxIEOuN{B2VQ>? NIXafVAyQSCqcoO= M136T2lvcGmkaYTpc44hd2ZiY1nBVFEwOiCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBVVk[jbIDoZUBt\X[nbDDheEAxNjN5IITvJFMvOyC3TTDh[pRmeiBzOTDodpMh[nliRVzJV2E> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
CHL1 NHXJ[4FHfW6ldHnvckBie3OjeR?= NF7rZYgxNjRidH:gNVAhfU1? NEHkT4szQCCqcoO= M3jVS2lvcGmkaYTpc44hd2ZiY1nBVFEhcW5iaIXtZY4hS0iOMTDj[YxteyCjdDCwMlQhfG9iMUCgeW0h[W[2ZYKgNlghcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NEW1O|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5N|k1OCd-MkSwPVM6PDB:L3G+
SKMES1 MYjGeY5kfGmxbjDhd5NigQ>? MVeyMlUhfU1? MkS4OUBl[Xm| NHLsTmNRd3SnboTpZZRqd25ib3[gZ49v[XS3bYXtZYIucW6mdXPl[EBieG:ydH;zbZMhcW5iaIXtZY4hW0uPRWOxJINmdGy|IHH0JFIvPSC3TTDh[pRmeiB3IHThfZMh[nliTWTTJIF{e2G7 Mn:4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
Capan1 MYXGeY5kfGmxbjDhd5NigQ>? MlPHNk42KHWP NH2wUZA2KGSjeYO= NET0OHpRd3SnboTpZZRqd25ib3[gZ49v[XS3bYXtZYIucW6mdXPl[EBieG:ydH;zbZMhcW5iaIXtZY4hS2GyYX6xJINmdGy|IHH0JFIvPSC3TTDh[pRmeiB3IHThfZMh[nliTWTTJIF{e2G7 NEfB[4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5N|k1OCd-MkSwPVM6PDB:L3G+
AGS MUPGeY5kfGmxbjDhd5NigQ>? NWO0fGZxOi53IIXN MW[1JIRigXN? Mnq4TY5lfWO2aX;uJI9nKHOnboPpeIl7[XSrb36gc4YhcHWvYX6gRWdUKGOnbHzzJJRwKGOxbnH0eY12dWGkLXnu[JVk\WRiYYDvdJRwe2m|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHH0JFIvPSC3TTDh[pRmeiB3IHThfZMh[nliTWTTJIF{e2G7 MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
U118MG NX:3fVl{TnWwY4Tpc44h[XO|YYm= M2TnN|IvPSC3TR?= NE\RW3E2KGSjeYO= M324cHBwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIFxd3C2b4Ppd{BqdiCqdX3hckBWOTF6TVegZ4VtdHNiYYSgNk42KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? M1XuVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzPVQxLz5{NEC5N|k1ODxxYU6=
PC3 MWrGeY5kfGmxbjDhd5NigQ>? NXzaWZlzOi53IIXN M2jPUVUh\GG7cx?= MkHkTY5lfWO2aX;uJI9nKHOnboPpeIl7[XSrb36gc4YhcHWvYX6gVGM{KGOnbHzzJJRwKGOxbnH0eY12dWGkLXnu[JVk\WRiYYDvdJRwe2m|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHH0JFIvPSC3TTDh[pRmeiB3IHThfZMh[nliTWTTJIF{e2G7 Mn2wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
CCRF-CEM MWDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NYLEOZBkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDR3JHNUOHTTDj[YxteyxiR1m1NEA:KDBwMkWg{txONg>? NV\mcodRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N|U2OjZpPkK4OFM2PTJ4PD;hQi=>
MDA-MB-231 MXLGeY5kfGmxbjDhd5NigQ>? NYrKUph4OiCqcoO= NEXYeY1KdmS3Y4Tpc44hd2ZiY1nBVFEh\GWpcnHkZZRqd25iaX6gbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCjZoTldkAzKGi{czygSWM2OCB;IECuNFAxPCEQvF2u NY\sRZBQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0PVI{OTdpPkK4OFkzOzF5PD;hQi=>
MDA-MB-231 NGjKenJEgXSxdH;4bYNqfHliYYPzZZk> NVfX[ZpjPzJiaILz NULpd3FsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDFR|UxKD1iMD6wNFc5KM7:TT6= NWXCcIV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0PVI{OTdpPkK4OFkzOzF5PD;hQi=>
HEK293 M2fOZWZ2dmO2aX;uJIF{e2G7 MVuyJIhzew>? NFXH[HpKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJGZNSUdvdHHn[4VlKFiLQWCgLJVvc26xd36gc5Jq\2mwKTDpcpRmemGldHnvckB4cXSqIH\1cIwhdGWwZ4ToJJVvfGGpZ3XkJINie3Cjc3WtPUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHntcZVvd3C{ZXPpdIl1[XSrb36gZZN{[XluIFXDOVAhRSByLkCzOUDPxE1w Mn2yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OUKzNVcoRjJ6NEmyN|E4RC:jPh?=
MDA-MB-231 NXLBOFIxSW62aYT1cY9zKGG|c3H5 MU[zNEBu\y:tZx?= MkXDNlQh\GG7cx?= MWjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KHinbn;ndoFnfGWmIHnuJGJidGJxYzDTR2lFKG2xdYPlJIF{e2W|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDNyIH3nM4toKGGmbXnubZN1\XKnZDD2bYEhd3KjbDDnZZZi\2ViZn;yJFI1KGSjeYO= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR7MkOxO{c,Ojh2OUKzNVc9N2F-
MDA-MB-231 MYrGeY5kfGmxbjDhd5NigQ>? MmHhNkBpenN? M1zySmlv\HWldHnvckBw\iCrboTyZYNmdGy3bHHyJINKSVBzIHTl[5Ji\GG2aX;uJIlvKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiMjDodpMtKEmFNUCgQUAxNjByMESg{txONg>? MoDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByOUG2NFAoRjNyMEmxOlAxRC:jPh?=
MDA-MB-231 Mn;mRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MXm3NkBpenN? NHf1ZYdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOC5yMEe4JO69VS5? NFfZ[no9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC5NVYxOCd-M{CwPVE3ODB:L3G+
HEK293 MnzLSpVv[3Srb36gZZN{[Xl? NXPNc|V5OiCqcoO= NIjORnRKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJGZNSUdvdHHn[4VlKFiLQWCgLJVvc26xd36gc5Jq\2mwKTDpcpRmemGldHnvckB4cXSqIH\1cIwhdGWwZ4ToJJVvfGGpZ3XkJINie3Cjc3WtPUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHntcZVvd3C{ZXPpdIl1[XSrb36gZZN{[XluIFnDOVAhRSByLkCzOUDPxE1w NGf5bpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC5NVYxOCd-M{CwPVE3ODB:L3G+
SKOV3 MWnBdI9xfG:|aYOgZZN{[Xl? NUf6fGtmPDhiaILz MmLpTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCVS1;WN{Bk\WyuczDhd5Nme3OnZDDjZZNx[XOnLUOgZYN1cX[jdHnvckBi\nSncjC0PEBpenNiYomgTY5kfUO7dHWgV|MhdGm4ZT3j[YxtKGGwYXz5d4l{NCCHQ{WwJF0hOC5yMEGg{txONg>? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTB7NUO4Okc,OzFyOUWzPFY9N2F-
SKOV3 NUnTXGpwSXCxcITvd4l{KGG|c3H5 M1fHUFI1KGi{cx?= Ml:2TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCVS1;WN{Bk\WyuczDhd5Nme3OnZDDjZZNx[XOnLUOgZYN1cX[jdHnvckBi\nSncjCyOEBpenNiYomgTY5kfUO7dHWgV|MhdGm4ZT3j[YxtKGGwYXz5d4l{NCCHQ{WwJF0hOC5yMEOg{txONg>? M3\hd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMEm1N|g3Lz5|MUC5OVM5PjxxYU6=
BL21(DE3) MXTGeY5kfGmxbjDhd5NigQ>? M3\v[FIhcHK| NELxfGxFcXOybHHj[Y1mdnRib3[gZolwfGmweXzheIVlKEGYUF[g[pJwdSCQLYTldo1qdmGuIFjpd{B1[WepZXSgdoVkd22kaX7hcpQhcHWvYX6gXGlCWC2ESWKzJIRwdWGrbjCoNlU{KHSxIEO0O{Bz\XOrZIXld{kh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUhFTTNrIHPlcIx{KGmwY4XiZZRm\CCob4KgNkBpenNiYomgSGVNTkmDLDDJR|UxKD1iMD6wOFgh|ryPLh?= NU\SS3U1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GwPVU{QDZpPkOxNFk2Ozh4PD;hQi=>
BL21(DE3) NH;nRY5HfW6ldHnvckBie3OjeR?= M4jkUlghcHK| NIH2eodFcXOybHHj[Y1mdnRib3[gZolwfGmweXzheIVlKEGYUF[g[pJwdSCQLYTldo1qdmGuIFjpd{B1[WepZXSgdoVkd22kaX7hcpQhcHWvYX6gXGlCWC2ESWKzJIRwdWGrbjCoNlU{KHSxIEO0O{Bz\XOrZIXld{kh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUhFTTNrIHPlcIx{KGmwY4XiZZRm\CCob4KgPEBpenNiYomgSGVNTkmDLDDJR|UxKD1iMD6wOVMh|ryPLh?= Mn;QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFyOUWzPFYoRjNzMEm1N|g3RC:jPh?=
A549 NF3kb2VHfW6ldHnvckBie3OjeR?= NHzXOYoyKHWP MnX4N{BpenN? Mnf3TY5lfWO2aX;uJI9nKGOLQWCyJIRm\3KjZHH0bY9vKGmwIHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOLQWCyJJBzd3SnaX6gcIV3\WxiYYSgNUB2VSCrbnP1ZoF1\WRiZn;yJFMhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF3NUCxOVUoRjNzNUWwNVU2RC:jPh?=
SK-MEL-28 NWjYUWpvTnWwY4Tpc44h[XO|YYm= MUOxJJVO M2SybFMhcHK| MXPJcoR2[3Srb36gc4Yh[0mDUEGg[IVoemGmYYTpc44hcW5iaIXtZY4hW0tvTVXMMVI5KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDjTWFROSCycn;0[YlvKGyndnXsJIF1KDFidV2gbY5kfWKjdHXkJIZweiB|IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= MlK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF3NUCxOVUoRjNzNUWwNVU2RC:jPh?=
SK-MEL-28 NXrJVVQyTnWwY4Tpc44h[XO|YYm= M1\wPFEhfU1? NEDJTJc{KGi{cx?= MkKxTY5lfWO2aX;uJI9nKGOLQWCyJIRm\3KjZHH0bY9vKGmwIHj1cYFvKFONLV3FUE0zQCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ2lCWDJicILveIVqdiCuZY\lcEBifCBzIIXNJIlv[3WkYYTl[EBnd3JiMzDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz NGfVcJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUW1NFE2PSd-M{G1OVAyPTV:L3G+
HEK293T MkfSSpVv[3Srb36gZZN{[Xl? NX3n[YFROTBidV2= M1PX[VYhcHK| MWXDc5ZidGWwdDDibY5lcW6pIHHm[olvcXS7IITvJGhCNUKLUkOg[I9u[WmwIH;mJHhKSVBiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gTGVMOjl|VDDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBj[W6mIHnueIVve2m2eTDheEAyOCC3TTDpcoN2[mG2ZXSg[o9zKDZiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= M{jLUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNUWwNVU2Lz5|MUW1NFE2PTxxYU6=
A549 MVPGeY5kfGmxbjDhd5NigQ>? MUGxJJVO M4TJVlMhcHK| NEXRcZNKdmS3Y4Tpc44hd2ZiY1nBVFEh\GWpcnHkZZRqd25iaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY1nBVFEheHKxdHXpckBt\X[nbDDheEAyKHWPIHnuZ5Vj[XSnZDDmc5IhOyCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTV3MEG1OUc,OzF3NUCxOVU9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cIAP1 / cIAP2 / XIAP / surivivin ; 

PubMed: 27737687     


A549 and H460 cells were treated for 48 h with 0-20 μM LCL161. The protein levels of cIAP1, cIAP2, XIAP and survivin were assessed by western blotting. β-actin was used as a loading control. The bar graphs represent the mean ± SD of different proteins/β-actin; *P < 0.05; **P < 0.01; ***P < 0.001

27737687
Growth inhibition assay
Cell viability; 

PubMed: 27737687     


Cells were treated for 48 h with the indicated concentrations of LCL161 and paclitaxel (c) or for the indicated times with 10 μM LCL161 and/or 10 μM paclitaxel (d). Cell viability was determined by the MTT assay. Data are represented as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001

27737687
In vivo LCL161 significantly enhances the ability of PKC412 to inhibit the growth of Ba/F3-FLT3-ITD-luc+ cells in vivo. LCL161 is also shown to positively combine with the standard chemotherapeutic agents, Ara-c and doxorubicin, against FLT3-ITD-expressing cells and against D835Y-expressing cells. There is an additive effect achieved by combining both Nilotinib and LCL161 in suppressing leukemia growth. LCL161 (100 mg/kg) enhances in vivo effects of high-moderate doses of nilotinib (100 mg/kg) on leukemia burden in mice. [1] CL161 is tested against the Pediatric Preclinical Testing Program (PPTP) in vivo panels (30 or 75 mg/kg [solid tumors] or 100 mg/kg [ALL]) administered orally twice in a week. LCL161 induces significant differences in EFS distribution in approximately one-third of solid tumor xenografts (osteosarcoma and glioblastoma), but not in ALL xenografts. No objective tumor responses are observed. In vivo LCL161 demonstrates limited single agent activity against the pediatric preclinical models studied. [2]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Human T-cell ALL cell lines COG-LL-317
  • Concentrations: ~10 μM
  • Incubation Time: 96 hours
  • Method:

    In vitro testing is performed using DIMSCAN


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (199.74 mM)
Water Insoluble
Ethanol '20 mg/mL warmed

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 500.63
Formula

C26H33FN4O3S

CAS No. 1005342-46-0
Storage powder
in solvent
Synonyms N/A
Smiles CC(C(=O)NC(C1CCCCC1)C(=O)N2CCCC2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03111992 Completed Drug: PDR001|Drug: CJM112|Drug: LCL161 Multiple Myeloma Novartis Pharmaceuticals|Novartis December 18 2017 Phase 1
NCT01934634 Unknown status Drug: LCL161|Drug: Gemcitabine|Drug: nab-Paclitaxel Metastatic Pancreatic Cancer US Oncology Research|Novartis Pharmaceuticals|Delta Clinical Research LLC March 2014 Phase 1
NCT01968915 Completed Drug: LCL161|Drug: Paclitaxel Neoplasms Novartis Pharmaceuticals|Novartis November 2013 Phase 1
NCT01617668 Completed Drug: LCL161|Drug: paclitaxel Breast Cancer Novartis Pharmaceuticals|Novartis August 2012 Phase 2
NCT01240655 Completed Drug: LCL161|Drug: Paclitaxel Solid Tumors Novartis Pharmaceuticals|Novartis April 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IAP Signaling Pathway Map

Tags: buy LCL161 | LCL161 supplier | purchase LCL161 | LCL161 cost | LCL161 manufacturer | order LCL161 | LCL161 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID